PriceTargets.com logo

Rani Therapeutics - RANI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.71
  • Forecasted Upside: 736.73%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$1.40 As of 12/20/2024 06:40 PM ET
▲ +0.1 (7.69%)

This chart shows the closing price for RANI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rani Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RANI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RANI

Analyst Price Target is $11.71
▲ +736.73% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Rani Therapeutics in the last 3 months. The average price target is $11.71, with a high forecast of $17.00 and a low forecast of $8.00. The average price target represents a 736.73% upside from the last price of $1.40.

This chart shows the closing price for RANI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Rani Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
10/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/16/2024HC WainwrightLower TargetBuy ➝ Buy$13.00 ➝ $9.00
8/2/2024OppenheimerInitiated CoverageOutperform$17.00
6/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
6/14/2024Maxim GroupInitiated CoverageBuy$15.00
6/13/2024Maxim GroupUpgradeStrong-Buy
6/13/2024Rodman & RenshawInitiated CoverageBuy$10.00
5/9/2024BTIG ResearchBoost TargetBuy ➝ Buy$7.00 ➝ $14.00
5/7/2024HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $13.00
3/27/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$21.00 ➝ $9.00
3/25/2024HC WainwrightLower TargetBuy ➝ Buy$16.00 ➝ $12.00
2/6/2024WedbushReiterated RatingOutperform ➝ Outperform$8.00
11/9/2023HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $16.00
9/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
9/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
8/21/2023Bank of AmericaLower TargetBuy ➝ Buy$19.00 ➝ $17.00
8/16/2023WedbushReiterated RatingOutperform ➝ Outperform$20.00
8/14/2023HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $20.00
7/10/2023Cantor FitzgeraldReiterated RatingOverweight
4/17/2023BTIG ResearchInitiated CoverageBuy$24.00
3/23/2023HC WainwrightReiterated RatingBuy$22.00
10/11/2022UBS GroupInitiated CoverageBuy
7/27/2022HC WainwrightInitiated CoverageBuy$22.00
6/13/2022WedbushInitiated CoverageOutperform ➝ Outperform
8/25/2021BTIG ResearchInitiated CoverageBuy$24.00
8/24/2021Stifel NicolausInitiated CoverageBuy$24.00
8/24/2021Cantor FitzgeraldInitiated CoverageOverweight$23.00
8/24/2021Bank of AmericaInitiated CoverageBuy$23.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Rani Therapeutics logo
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Read More

Today's Range

Now: $1.40
Low: $1.30
High: $1.42

50 Day Range

MA: $2.15
Low: $1.30
High: $3.18

52 Week Range

Now: $1.40
Low: $1.30
High: $8.75

Volume

460,055 shs

Average Volume

550,562 shs

Market Capitalization

$80.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Rani Therapeutics?

The following sell-side analysts have issued stock ratings on Rani Therapeutics in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., HC Wainwright, Maxim Group, Oppenheimer Holdings Inc., Rodman & Renshaw, and Wedbush.
View the latest analyst ratings for RANI.

What is the current price target for Rani Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Rani Therapeutics in the last year. Their average twelve-month price target is $11.71, suggesting a possible upside of 736.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting RANI will reach $17.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $8.00 for Rani Therapeutics in the next year.
View the latest price targets for RANI.

What is the current consensus analyst rating for Rani Therapeutics?

Rani Therapeutics currently has 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RANI will outperform the market and that investors should add to their positions of Rani Therapeutics.
View the latest ratings for RANI.

What other companies compete with Rani Therapeutics?

Other companies that are similar to Rani Therapeutics include Cryoport, Design Therapeutics, Procaps Group, biote and Neurogene. Learn More about companies similar to Rani Therapeutics.

How do I contact Rani Therapeutics' investor relations team?

The company's listed phone number is 408-457-3700 and its investor relations email address is [email protected]. The official website for Rani Therapeutics is www.ranitherapeutics.com. Learn More about contacing Rani Therapeutics investor relations.